Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis. Adam Feuerstein, senior columnist at TheStreet, breaks down the study results of the TRAFFIC and TRANSPORT phase III studies, which when pooled together, resulted in a 3.3% improvement in cystic fibrosis patients' lung function on an absolute basis. Feuerstein reveals whether the results are clinically meaningful and how significant they're likely to be regarded by industry watchers. With the stock soaring pre-market on the news, Feuerstein also explains what the results should mean to shares of Vertex going forward.

More from Video

BlackBerry CEO Talks Impact of Trump's Tariffs Among His Big Automaker Clients

BlackBerry CEO Talks Impact of Trump's Tariffs Among His Big Automaker Clients

Trump Sowing the Seeds of a 10% Stock Market Correction?

Trump Sowing the Seeds of a 10% Stock Market Correction?

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Video: Here's When Investors May Start to Withstand Tough Trade Talk

Video: Here's When Investors May Start to Withstand Tough Trade Talk

Jim Cramer's Investing Rule 17: Check Hope at the Door

Jim Cramer's Investing Rule 17: Check Hope at the Door